Business Description
Helix BioPharma Corp. is a Canadian drug development company focused on fighting cancer by targeting the environment around tumors that helps them survive and grow. Its lead treatment, L-DOS47, is an experimental compound currently being tested in multiple clinical trials for lung and pancreatic cancers, while a related compound, V-DOS47, is being developed to cut off the blood supply tumors rely on. The company works alongside leading research institutions, including Moffitt Cancer Center and the University Hospital Tuebingen, to better understand how its treatments work and how they might be combined with other cancer therapies. Founded in 2008 and based in Vancouver, Helix also holds a licensing agreement covering potential applications of one of its compounds in metabolic and fat tissue-related conditions.
